Q3 FY26 results with qualified auditor opinion on Labour Codes
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.5 pts more than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indo US Bio-Tech posted Q3 FY26 revenue of Rs 2,279.83 lakhs, down about 3 percent YoY from Rs 2,356.35 lakhs. Nine-month revenue grew nearly 20 percent to Rs 8,441.44 lakhs from Rs 7,045.38 lakhs. Net profit fell sharply to Rs 299.66 lakhs in Q3 from Rs 505.45 lakhs, and to Rs 1,115.11 lakhs for 9 months from Rs 1,258.28 lakhs. EPS stood at Rs 1.49 versus Rs 2.52. Auditor Gautam N Associates issued a qualified opinion, flagging the company's incomplete assessment of incremental liability from the new Labour Codes effective November 2025.
Qualified auditor opinion and weak Q3 profit may weigh on sentiment. Labour Codes impact assessment remains pending.